Shield Therapeutics (LON:STX) Shares Up 1.6% - What's Next?

Key Points

• Shares rose 1.6% to GBX 9.50 on Wednesday (intraday high GBX 9.70), but trading was light at 448,511 shares—about a 78% decline from the ~2.01M average session volume.
• Financial/technical snapshot: Market cap £101.46M, negative PE (-4.75), 50‑day/200‑day SMAs at GBX 8.99/9.18, and mixed liquidity/leverage metrics (quick ratio 2.16, current ratio 0.90, debt‑to‑equity reported as negative).
• Commercial-stage business: Shield markets Accrufer®/Feraccru® (ferric maltol) for iron deficiency, has launched in the U.S. through an exclusive multi‑year commercial agreement with Viatris, and has licensed rights to partners outside the U.S.

Shield Therapeutics plc (LON:STX - ) shares shot up 1.6% during trading on Wednesday . The stock traded as high as GBX 9.70 and last traded at GBX 9.50. 448,511 shares were traded during trading, a decline of 78% from the average session volume of 2,006,339 shares. The stock had previously closed at GBX 9.35.

Shield Therapeutics Price Performance

The firm has a fifty day simple moving average of GBX 8.99 and a 200 day simple moving average of GBX 9.18. The company has a market capitalization of £101.46 million, a PE ratio of -4.75 and a beta of 1.92. The company has a debt-to-equity ratio of -199.87, a quick ratio of 2.16 and a current ratio of 0.90.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.